Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...

Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.

SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...

New treatments based on biological molecules like RNA give scientists unprecedented control over how cells function. But ...

Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

The American Heart Association released its 2026 Heart Disease and Stroke Statistics Update, and a reminder that heart ...

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...

Arrowhead Pharmaceuticals recently reported dosing the first subjects in a Phase 1/2a trial of ARO-DIMER-PA, an RNAi drug candidate designed to silence both PCSK9 and APOC3 to address atherosclerotic ...

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment ...

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...

Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...